Universität zu Köln

2017

Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Seiler, T., von Weikersthal, L. Fischer, Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Haematologica, 102. S. 171 - 173. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Tausch, E., Seiler, T., von Weikersthal, Fischer L., Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 40. S. 24 - 25. BASEL: KARGER. ISSN 2296-5262

2016

Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A. M., Pflug, N., Engelke, A., von Tresckow, J., Kovacs, G., Stilgenbauer, S., Wendtner, C-M, Mueller, L., Ritgen, M., Seiler, T., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. Leukemia, 30 (10). S. 2019 - 2026. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551